Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein 91 homolog (ZFP91)
- Target
- ZFP91
- Molecular classification
- Transcription factor (C2H2-type zinc finger protein, part of the KRAB [Kruppel-associated box] subfamily), E3 ubiquitin-protein ligase
01
Overview
Zinc finger protein 91 homolog is a nuclear protein and transcription factor encoded by the human ZFP91 (also ZNF91) gene on chromosome 19. It contains multiple C2H2-type zinc finger domains, a KRAB domain, and functions in DNA binding to regulate the expression of various genes. ZFP91 is critical for the suppression of SVA retrotransposons by binding to their sequences and assembling a repressive complex with TRIM28/KAP1. It also regulates gene promoters and is involved in activating the non-canonical NF-κB signaling pathway via NIK ubiquitinization. Overexpression of ZFP91 has been linked to increased tumor proliferation, migration, invasion, and chemoresistance, particularly in pancreatic and other cancers. Overall, Zinc finger protein 91 homolog represents an important transcriptional regulator with clinical significance in oncology and potentially other human diseases.
- Other names
- ZNF91HPF7HTF10zinc finger protein 91
02
Mechanism of action
Drugs targeting this molecule may inhibit its transcriptional activity, disrupt DNA binding, or modulate its ubiquitin-ligase function, especially impacting NF-κB pathway and tumor cell proliferation
03
Biological functions
Transcriptional regulation (acts as both enhancer and repressor of gene transcription)Suppression of retrotransposons, especially SINE-VNTR-Alu (SVA) elementsProtein-protein interactionsRegulation of NF-κB signaling pathway (activates non-canonical pathway via NIK)Potential involvement in glycolysis and chemoresistance in cancer
04
Disease associations
Cancer (especially leukemia, melanoma, pancreatic, breast, lung, sarcoma, colon, endometrial cancers)Tumorigenesis and cancer progressionPotentially neurodegenerative diseases, skin diseases, diabetes, based on zinc finger protein family
05
Safety considerations
Therapeutic targeting could disrupt normal transcriptional regulatory mechanisms, with possible effects on immune function and cell differentiation, due to ZFP91’s widespread roles
06
Interacting drugs
No approved targeted drugs for ZFP91/ZNF91 currently listed in public databases or literature. The targeting of zinc finger proteins in cancer is under preclinical and exploratory research.
07
Biomarkers
High expression of ZFP91 (ZNF91) in certain cancers (e.g., sarcoma, melanoma, pancreatic cancer) may serve as a biomarker for prognosis or therapeutic response
Beyond the preview
Go deeper on Zinc finger protein 91 homolog (ZFP91).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zinc finger protein 91 homolog (ZFP91).